Filing Flows › Arcadia Biosciences (RKDA) › Q1 2026 › vs Q1 2025
Arcadia Biosciences (RKDA) Q1 2026 vs Q1 2025 (year over year)
Arcadia Biosciences's revenue fell $100K (-8%) from $1.2M in Q1 2025 to $1.1M in Q1 2026.
Arcadia Biosciences, Q1 2026: revenue $1.1M (-8% year over year), operating margin -70.8%, net loss $4.4M, operating cash flow −$1.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1M | $1.2M | −$100K | -8% |
| Net loss | $4.4M | −$2.6M | $7.0M | — |
| Costs & expenses | $5.5M | $3.3M | $2.2M | +68% |
| Operating costs | $1.9M | $670K | $1.2M | +180% |
| Interest & other, net | $3.6M | −$2.1M | $5.7M | — |
| Operating cash sources | $4.4M | −$2.6M | $7.0M | — |
| Depreciation | $8K | $13K | −$5K | -38% |
| Share-based compensation | $15K | $78K | −$63K | -81% |
| Working capital & other | $3.3M | −$4.3M | $7.5M | — |
| Cash used in operations | $1.1M | $1.6M | −$489K | -31% |
| Net loss absorbed | $4.4M | −$2.6M | $7.0M | — |
Questions
How much did Arcadia Biosciences's revenue grow year over year in Q1 2026?
Arcadia Biosciences's revenue fell $100K (-8%) from $1.2M in Q1 2025 to $1.1M in Q1 2026.